Mechanisms of infliximab: the reverse side of a drug effect.
Waetzig
Georg H
GH
Conaris Research Institute AG, Kiel, Germany.
Schreiber
Stefan
S
D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D003424:Crohn Disease / Q000188:drug therapy*; D000069285:Infliximab; D020928:Mitogen-Activated Protein Kinases / Q000187:drug effects; D015398:Signal Transduction / Q000187:drug effects; D048051:p38 Mitogen-Activated Protein Kinases
D000911:Antibodies, Monoclonal; D000069285:Infliximab; D020928:Mitogen-Activated Protein Kinases; D048051:p38 Mitogen-Activated Protein Kinases